ANIMATION

HuLuc 63

Share this animation:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Share It:
Contact XVIVO

Client


PDL BioPharma

XVIVO’s professional team met the many challenges posed by a pre-launch product and rendered visually compelling, high quality animations.

Vice President, Management Supervisor, Ogilvy Healthworld Medical Education
Share this animation: